We also noted that FLT3-ITD status was not associated with the responses of cells to FLT3/PKCi (Fig. 2c, Figure S5b), an inhibitor recently approved to treat FLT3 mutant AML [14]. The gene discussed is FLT3; the disease is acute myeloid leukemia.